Company intelligence / Profile preview

AgaMatrix

Salem, New Hampshire, United Statesagamatrix.com ↗

Ownership: Private
Development stage: Commercial

Overview

AgaMatrix has developed over ten FDA-cleared products since its founding in 2001. Its WaveSense platform powers a range of blood glucose meters and test strips with high accuracy. The company was the first to receive FDA approval for a smartphone-linked diagnostic device. Its products are widely used globally—including partnerships with Sanofi—and supply over one million test strips per month to the NHS in the UK.

Therapeutic areas: Endocrinology
Modalities: Device (blood glucose monitoring devices)Digital health solution (connected diabetes management)Diagnostic technology (electrochemical biosensors)
Industry: Metabolite Diagnostics

Partnerships

Sanofi/Sanofi-Aventis (co-development of BGStar/iBGStar devices)NHS UK supply partnership

Beyond the preview

Go deeper on AgaMatrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AgaMatrix.

Explore the full profile